Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

TOKYO, Sept. 16, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and…

Emerging Tau-Targeting Antibody for Alzheimer’s Disease Gets FDA Fast Track Designation

Preliminary research findings have shown that the investigational anti-microtubule binding region (MTBR) tau antibody etalanetug may help reduce a biomarker for brain tau pathophysiology and tau signals on positron emission tomography (PET).

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation – EastMud

Open the article to view the coverage from eastmud.com

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation – DIR HONGKONG

Open the article to view the coverage from dirhongkong.com